Milano (1)

Padova (1)

Triple Negative Breast Cancer Metastatic (1)

Recruiting (1)

phase 2 (1)

IFOM, The FIRC Institute of Molecular Oncology (1)

AstraZeneca (1)

ceralasertib (1)

durvalumab (1)

nab-paclitaxel (1)

drug (1)

Other (1)

Interventional (1)

triple negative breast cancer metastatic

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Jan 16, 2023